Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.LONA · Entity 1487 | Director | April 09, 2026 | April 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date April 09, 2026 · Filed April 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.54 · Expires 2036-04-08 | Direct | 28,000 |
Reported balance
After 2026-04-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-09 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2026 Filed Apr 13, 2026 20:49 UTC | LeonaBio, Inc. LONA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $9.54 | $0.00 |
DisclosureSEC source: 0001191906-26-000002 · form4-04132026_080445.xml · derivative · entry 1 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-04-08 F1 · derivative.exercise_date: The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 21:37 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001415889-25-015441 · form4-06032025_090659.xml · derivative · entry 1 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2035-05-29 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 30, 2026, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| May 24, 2024 Filed May 24, 2024 22:54 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001415889-24-014569 · form4-05242024_100557.xml · derivative · entry 1 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2034-05-23 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 24, 2025, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 24, 2024. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:58 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-23-031557 · doc4.xml · derivative · entry 1 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2033-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 19, 2024, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 19, 2023. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| May 20, 2022 Filed May 27, 2022 21:42 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 13,871 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001209191-22-032687 · doc4.xml · derivative · entry 1 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,871 Underlying: Common Stock · 13,871 shares Expires 2032-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 22:50 UTC | LeonaBio, Inc. ATHA · Entity 1487 | OtherCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041084 · doc4.xml · nonDerivative · entry 2 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,884 F4 · kind: Acquisition by the Reporting Person pursuant to the Distribution. F4 · price: Acquisition by the Reporting Person pursuant to the Distribution. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 22:50 UTC | LeonaBio, Inc. ATHA · Entity 1487 | OtherCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041084 · doc4.xml · nonDerivative · entry 1 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Fluke Capital Management, L.P. Disclosed balance after: 3,731 F1 · kind: Fluke Capital Management, L.P. distributed these shares to its partners on a pro rata basis for no consideration (the "Distribution"). F1 · price: Fluke Capital Management, L.P. distributed these shares to its partners on a pro rata basis for no consideration (the "Distribution"). F2 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.nature: The Reporting Person is a director of Fluke Management Corp., which is the managing general partner of Fluke Capital Management, L.P. The Reporting Person is also a partner of Fluke Capital Management, L.P. By virtue of such relationships, Mr. Fluke may be deemed to have voting and investment power with respect to the shares held by Fluke Capital Management, L.P. and as a result may be deemed to have beneficial ownership of such shares. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:25 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 13,871 | $0.00 Strike: $19.94 | $0.00 |
DisclosureSEC source: 0001209191-21-036919 · doc4.xml · derivative · entry 1 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,871 Underlying: Common Stock · 13,871 shares Expires 2031-05-27 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 28, 2022, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 28, 2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:18 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,783 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-21-007925 · doc4.xml · derivative · entry 5 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,783 shares Expires 2030-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 13, 2019. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:18 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,220 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-21-007925 · doc4.xml · derivative · entry 4 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,220 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option fully vested on December 13, 2020. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:18 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 3,783 | $1.35 | $5,107.05 |
DisclosureSEC source: 0001209191-21-007925 · doc4.xml · nonDerivative · entry 2 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This filing relates to the exercise of stock options. No shares of Common Stock were sold by Mr. Fluke, and the shares of Common Stock received upon exercise of the stock options are subject to lock-up agreements with Goldman Sachs & Co. LLC and Jefferies LLC. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:18 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 25,220 | $1.19 | $30,011.80 |
DisclosureSEC source: 0001209191-21-007925 · doc4.xml · nonDerivative · entry 1 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This filing relates to the exercise of stock options. No shares of Common Stock were sold by Mr. Fluke, and the shares of Common Stock received upon exercise of the stock options are subject to lock-up agreements with Goldman Sachs & Co. LLC and Jefferies LLC. Read SEC document |
| September 22, 2020 Filed Sep 22, 2020 21:16 UTC | LeonaBio, Inc. ATHA · Entity 1487 | ConversionSeries B-1 Preferred Stock · Derivative | 6,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051512 · doc4.xml · derivative · entry 6 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Fluke Capital Management, L.P. Disclosed balance after: 0 Underlying: Common Stock · 6,731 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · kind: Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.exercise_date: Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.expiration_date: Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| September 22, 2020 Filed Sep 22, 2020 21:16 UTC | LeonaBio, Inc. ATHA · Entity 1487 | ConversionSeries A-1 Preferred Stock · Derivative | 51,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051512 · doc4.xml · derivative · entry 5 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,831 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · kind: Each share of Series A-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.exercise_date: Each share of Series A-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.expiration_date: Each share of Series A-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| September 22, 2020 Filed Sep 22, 2020 21:16 UTC | LeonaBio, Inc. ATHA · Entity 1487 | ConversionSeries A Preferred Stock · Derivative | 12,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051512 · doc4.xml · derivative · entry 4 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · kind: Each share of Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| September 22, 2020 Filed Sep 22, 2020 21:16 UTC | LeonaBio, Inc. ATHA · Entity 1487 | ConversionCommon Stock | 6,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051512 · doc4.xml · nonDerivative · entry 3 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Fluke Capital Management, L.P. Disclosed balance after: 6,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| September 22, 2020 Filed Sep 22, 2020 21:16 UTC | LeonaBio, Inc. ATHA · Entity 1487 | ConversionCommon Stock | 51,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051512 · doc4.xml · nonDerivative · entry 2 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Each share of Series A-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| September 22, 2020 Filed Sep 22, 2020 21:16 UTC | LeonaBio, Inc. ATHA · Entity 1487 | ConversionCommon Stock | 12,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051512 · doc4.xml · nonDerivative · entry 1 FLUKE JOHN M JR · CIK 0001191906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.